



## BIO MEDICA LABORATORIES PVT. LTD.

NOTICE IS HEREBY GIVEN THAT 8<sup>TH</sup> ANNUAL GENERAL MEETING OF THE MEMBERS OF BIO MEDICA LABORATORIES PRIVATE LIMITED("COMPANY") WILL BE HELD ON SATURDAY, 30<sup>TH</sup> SEPTEMBER, 2023 AT 11.30A.M IST AT THE REGISTERED OFFICE OF THE COMPANY AT PLOT NO. 254, SECTOR-F, SANWER ROAD, INDUSTRIAL AREA, INDORE - 452015 TO TRANSACT THE FOLLOWING ITEMS OF BUSINESS:

### Ordinary Business:

**ITEM NO. 1** -To consider and adopt the Annual Audited financial statements of the Company for the financial year ended March 31, 2023, consisting of the Balance Sheet, Statement of Profit and Loss and notes thereon, together with the reports of the Board of Directors and Auditors thereon.

**ITEM NO. 2 – Appointment of Statutory Auditor of the Company to fill casual vacancy caused by resignation of M/s. LUNAWAT & SOMANI, CHARTERED ACCOUNTANTS**

To consider and appoint the statutory auditors of the Company and if thought fit, to pass, with or without modification(s) the following resolution as **Ordinary Resolution**:

**"RESOLVED THAT** pursuant to the provisions of Section 139 (8) of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 and other applicable provisions, if any, (including any statutory modification(s), clarifications, exemptions or re-enactments thereof for the time being in force), **M/s Akshay Vijawat & Co., Chartered Accountants**, having (FRN.: 023175C), be and are hereby appointed as Statutory Auditors of the Company, to fill the casual vacancy caused by the resignation of **M/s. Lunawat & Somani, Chartered Accountants**.

**RESOLVED FURTHER THAT M/s Akshay Vijawat & Co., Chartered Accountants**, having (FRN.: 023175C), be and is hereby appointed as Statutory Auditors of the Company from ensuing Annual General Meeting and that they shall hold the office of the Statutory Auditors of the Company from the conclusion of this Annual General Meeting till the conclusion of Annual General Meeting of the Company to be held in 2028 on such remuneration and out-of-pocket expenses, as may be mutually agreed with the Board of Directors."

**RESOLVED FURTHER THAT** any director of the company, be and is hereby authorised to do all such acts, deeds and things as may be necessary to give effect to the said resolution and file Form ADT-1 for above appointment with the Registrar of Companies."

**By order of the Board of Directors**

**For Bio Medica Laboratories Private Limited**

**Pradeep Mehta**  
**Director**

**DIN: 07254802**  
**Date: 02.09.2023**  
**Place: Indore**



Registered Office:  
PLOT NO. 254, SECTOR-F,  
SANWER ROAD, INDUSTRIAL AREA,  
INDORE - 452015

**NOTES:**

1. Notice is sent to all the shareholders, whose names appear in the Register of Members as on the date of notice.
2. *A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON POLL INSTEAD OF HERSELF/HIMSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY.* A person can act as proxy on behalf of members not exceeding 50 (Fifty) and holding in the aggregate not more than ten percent of the total share capital of the Company. Instrument of proxy, to be effective, must be deposited at the Registered Office of the Company not less than 48 hours before the commencement of the meeting.
3. A Proxy form is attached to the notice. Proxies submitted on behalf of the Companies, Societies, etc, must be supported by an appropriate resolution/authority, as applicable.
4. During the period beginning 24 hours before the time fixed for the commencement of Meeting and ending with the conclusion of the Meeting, a member would be entitled to inspect the proxies lodged at any time during the business hours of the Company.
5. Members / proxies should bring their attendance slip duly filled and signed for attending the meeting.
6. The documents referred to in the accompanying Notice and the Statements are open for inspection by the members at the registered office of the Company on all working days except Saturdays and Sundays (including public holidays), during business hours up to the date of this meeting.
7. Route map of the venue of this meeting is appended at the end of this notice.



Form No. MGT-11

Proxy form

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: U24230MP2015PTC034576

Name of the Company: BIO MEDICA LABORATORIES PRIVATE LIMITED

Registered Office: Plot-254, Sector-F Sanwer Road, Indore, Indore, Madhya Pradesh, India, 452015

Name of the member(s):

Registered address:

E-mail Id:

Folio No/ Client Id:

DP ID:

I/We being the member(s) of \_\_\_\_\_ shares, of the above named company, hereby appoint

1. Name:

Address:

E-mail Id:

Signature: \_\_\_\_\_, or failing him

as my / our proxy to attend and vote (on a poll) for me / us and on my / our behalf at the Annual General Meeting/ ~~Extraordinary General Meeting~~ of shareholders of the Company, to be held on Saturday, the 30<sup>th</sup> day of September 2023, at 11:30 a.m. at Plot-254, Sector-F Sanwer Road, Indore, 452015 and at adjournment thereof in respect of such resolutions as are indicated below:

Sr. No.	Resolution
1	Ordinary resolution for adoption of annual accounts along with auditors' and directors' report for Financial Year 2022-23;
2	Ordinary Resolution for appointment of statutory auditors of the Company

Signed this.....day of .....2023

Affix Re.1/-  
Revenue Stamp

\_\_\_\_\_  
Signature of Shareholder

\_\_\_\_\_  
Signature of Proxy holder(s)

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.





**Attendance slip**

**BIO MEDICA LABORATORIES PRIVATE LIMITED**

**CIN: U24230MP2015PTC034576**

**Regd. Office: PLOT-254, SECTOR-F SANWER ROAD, NA, INDORE - 452015**

I hereby record my presence at the Annual General Meeting of the Company held at Plot-254, Sector-F Sanwer Road, Indore, 452015, at 11:30 a.m. on Friday, the 30<sup>th</sup> day of September 2022.

\_\_\_\_\_  
Full name of the Member (in block letters)

\_\_\_\_\_  
No. of shares held

\_\_\_\_\_  
Signature of member

Folio No: \_\_\_\_\_ DP ID No.\* \_\_\_\_\_ Client ID No\* \_\_\_\_\_

Applicable for member holding shares in dematerialized / electronic form.

\_\_\_\_\_  
Full name of the Proxy (in block letters)

\_\_\_\_\_  
No. of shares

\_\_\_\_\_  
Signature of Proxy

**NOTE:** Member attending in person/proxy holder wishing to attend the meeting are requested to bring the attendance slip and hand it over at the entrance of the meeting place.



Route Map(with prominent landmark) of the venue of the Annual General Meeting is appended at the end of the Notice:



**DIRECTORS REPORT**

Dear Members,

Your Directors have pleasure in presenting this 8<sup>th</sup> Annual report on the affairs of the Company together with the Audited Statement of Accounts for the year ended on 31<sup>st</sup> March, 2023

**1. Financial Summary or performance of the company:**


( in Rs.)

<b>PARTICULARS</b>	<b>2022-23</b>	<b>2021-22</b>
1.NET SALES	162281784	212252005
2A.OTHER OPERATING INCOME	-	-
2B.OTHER INCOME	492900	2118338
<b>3.TOTAL INCOME(1+2A+2B)</b>	<b>162774684</b>	<b>214370343</b>
A) COST OF MATERIAL CONSUMED	115870739	148843972
B) PURCHASE OF STOCK IN TRADE		21159615
C) CHANGES IN INVENTORIES OF FINISHEDGOODS	(1189241)	(2888281)
D) EMPLOYEE BENIFITS EXPENSES	18123090	17265519
G) OTHER EXPENSES	12393802	11059336
<b>4. TOTAL EXPENSES</b>	<b>145198390</b>	<b>195440161</b>
<b>5. EBDIT(3-4+E+F)</b>	<b>17576294</b>	<b>18930182</b>
6. INTEREST	7732846	7675628
7. DEPRECIATION	4966774	3281483
<b>8.PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX(5-6-7)</b>	<b>4876674</b>	<b>7973070</b>
9.CURRENT TAX & EARLIER TAX	1257074	2109125
10.MAT CREDIT RECEIVABLE	-	-
11.DEFERRED TAX	21014	(26057)
<b>12.NET PROFIT AFTER TAX</b>	<b>3598586</b>	<b>5890002</b>

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director

**\*Previous year figures have been regrouped/ rearranged wherever necessary**

## **2. Operations**

The Company has reported Gross receipt of ₹ 162,281,784/- for the current year as compared to ₹ 212,252,005/- in the previous year. The Net Profit for the year under review amounted to ₹ 35,98,586/- in the current year as compared to Profit of ₹ 58,90,002/- in the previous year.

## **3. Transfer to reserves**

The Company proposes to carrying a total reserve & surplus of ₹ 2,61,33,879 /- including current year's Profit.

## **4. State of Company's Affairs and Future Outlook**

Your directors are taking the best efforts so as to maximize the profits of the Company. During the year Company has made such investments which will give fruitful results in the year to come.

## **5. Disclosure regarding Issue of Equity Shares with Differential Rights: NA**

## **6. Disclosure regarding issue of Employee Stock Options: NA.**


## **7. Disclosure regarding issue of Sweat Equity Shares: NA**

## **8. Dividend**


Your directors do not recommend any dividend for financial period 2022-23.

## **9. Extract of Annual Return**

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,



Director.



The extract of Annual Return, in format MGT -9, for the Financial Year 2022-23 has been enclosed with this report.

**10. Material Changes between the date of the Board report and end of financial year :-**

There have been no material changes and commitments, if any, affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report.

**11. Significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future:**

During the year under review there has been no such significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future.

**12. Subsidiary Company:**

As on March 31, 2023, the Company does not have any subsidiary.

**13. Statutory Auditor & Audit Report:**

M/s. Lunawat & Somani, Chartered Accountants, statutory auditors of the Company having Firm Registration Number 012609C has resigned from this Annual General Meeting and M/s Akshay Vijawat & Co. Chartered Accountants, appoint statutory auditors of the Company having Firm Registration Number 023175C hold office from 9<sup>th</sup> AGM until the conclusion of the 13<sup>th</sup> Annual General Meeting subject to the ratification of the members at every general meeting. Further, the report of the Statutory Auditors alongwith notes to Schedules is enclosed to this report. The observations made in the Auditors' Report are self-explanatory and therefore do not call for any further comments.

**14. Change in the nature/Name of business :-**

There is no change in the nature or name of the business of the company

**15. Corporate Social Responsibility:**

The Company is not required to constitute a Corporate Social Responsibility Committee as it does not fall within purview of Section 135(1) of the Companies Act, 2013 and hence it is not required to formulate policy on corporate social responsibility.


**16. Number of meeting of the Board:**

During the year 2022-23, the Board of Directors met Six times viz. on 12/06/2022; 02/09/2022; 29/09/2022, 02/12/2022, 08/02/2023 and 31/03/2023.

**17. Directors' Responsibility Statement:**

Pursuant to the requirement under section 134(3) (C) of the Companies Act, 2013 with respect to Directors' Responsibility Statement, it is hereby confirmed that:

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.



(i) In the preparation of the annual accounts for the financial year ended 31<sup>st</sup> March, 2023, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(ii) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2023 and of the profit and loss of the company for that period;

(iii) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(iv) The directors had prepared the annual accounts on a going concern basis.

(vi) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

#### **18. Declaration by Independent Directors:**

The Company was not required to appoint Independent Directors under Section 149(4) and Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014 hence no declaration has been obtained.

#### **19. Company's policy on directors' appointment and remuneration including criteria for determining qualifications, positive attributes, independence of a director and other matters provided under sub-section (3) of section 178;**

The Company, being a Private Limited Company was not required to constitute a Nomination and Remuneration Committee under Section 178(1) of the Companies Act, 2013 and Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Stakeholders Relationship Committee under Section 178(5) of the Companies Act, 2013.

#### **15. Particulars of loans, guarantees or investments under section 186:**

During the year under review, the Company has not advanced any loans/ given guarantees/ made investments.

#### **16. Particulars of Employee:**

None of the employee has received remuneration exceeding the limit as stated in rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

#### **17. Voluntary Revision of Financial Statements or Board's Report: NA**

#### **18. Statement in Respect of Adequacy of Internal Financial Control with Reference to the Financial Statements: NA**

#### **19. Secretarial Audit Report: NA**

#### **20. Re-appointment of Independent Auditor: NA**


#### **21. Corporate Social Responsibility (CSR) Policy: NA**

#### **22. Audit Committee: NA**

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

**23. Managerial remuneration:**

During the year Company has paid amount of Rs. 48,00,000/- as Managerial Remuneration (Including Bonus) to the Directors of the company.

**24. Particulars of contracts or arrangements with related parties: -**

The particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act 2013 for the Financial Year 2022-23 in the prescribed format, AOC 2 has been enclosed with the report.

**25. Details of Directors and Key Managerial Personnel**

The Board consists of the following directors namely:-

DIN NO	NAME	DESIGNATION	DATE OF APPOINTMENT	DATE OF RESIGNATION
07254802	PRADEEP MEHTA	Director	14/08/2015	NA
03187420	MUKESH MEHTA	Director	14/08/2015	NA

**26. Risk management policy:-**

It may be noted that as per the applicable requirement of Companies Act, 2013 a risk management policy of the Company is developed and implemented and Board reviews the same periodically for creating and protecting the Shareholder's value by minimizing threats or losses and to identify and provide a framework that enables future activities of a Company to take place in a consistent and controlled manner.

**27. Details on conservation of energy, technology absorption, foreign exchange earnings and outgo:-**

Information as per Section 134(3)(m) of the Companies Act, 2013, read with Companies (Accounts) Rules, 2014 and forming part of the Directors' Report to the members for the year ended 31st March, 2023.

- 1. Conservation of Energy:** - The activities carried out by the Company are not power intensive and the cost of the energy is insignificant. The Company is not utilizing alternate sources of energy.
- 2. Technical Absorption:-** The Company has not imported any technology during the year. There is no specific amount spent for research and development.

**28. Statement Indicating the Manner in which Formal Annual Evaluation has been made by the Board of its own Performance, its Directors, and that of its Committees: NA****29. Nomination & Remuneration Committee Policy: NA**


For Bio-Medica Laboratories Pvt. Ltd.,

**30. Disclosure on Establishment of a Vigil Mechanism: NA**


Director.

**31. Corporate Governance: NA**

For Bio-Medica Laboratories Pvt. Ltd.,



Director.

**32. Formal evaluation by board of its own performance:-**

It may please be noted that the Statement in respect of Formal Evaluation by the Board of its own performance and that of its committees and individual directors is not applicable to the Company.

**33. Internal Financial Controls**

The company is having adequate internal financial controls with reference to the financial statements in terms of Section 134 (3) (g) of Companies Act, 2013 read with Rule 8 (5) (viii) of Companies (Accounts) Rules, 2014.

**Acknowledgement:**

Your Directors wish to place on record their sincere appreciation and gratitude for the valuable support and co-operation received from the Customers and Suppliers, various Financial Institutions, Banks, Government Authorities, Auditors and Shareholders during the year under review. Your Directors wish to place on record their deep sense of appreciation for the devoted services of the Executives, Staff and Workers of the Company for its success Your Directors also thank the Central and State Governments, and other statutory authorities for their continued support.

**For and on behalf of board of directors**

For Bio-Medica Laboratories Pvt. Ltd.,

**Mukesh Mehta**  
Director  
DIN: 03187420

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

**Pradeep Mehta**  
Director  
DIN: 07254802

  
Director.

**Date: 02.09.2023**

**Place: Ipore**



FORM NO. AOC-2

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)


1. Details of contracts or arrangements or transactions not at arm's length basis
  - (a) Name(s) of the related party and nature of relationship
  - (b) Nature of contracts/arrangements/transactions
  - (c) Duration of the contracts/arrangements/transactions
  - (d) Salient terms of the contracts or arrangements or transactions including the value, if any
  - (e) Justification for entering into such contracts or arrangements or transactions
  - (f) date(s) of approval by the Board
  - (g) Amount paid as advances, if any:
  - (h) Date on which the special resolution was passed in general meeting as required under first proviso to section 188
2. Details of material contracts or arrangement or transactions at arm's length basis
  - (a) Name(s) of the related party and nature of relationship: Tara Mehta, Garima Mehta, Anju Mehta, Lokesh Mehta, Mukesh Mehta, Pradeep Mehta, Bio Medica Parenteral
  - (b) Nature of contracts/arrangements/transactions - Salary, Interest, Supervision Charges
  - (c) Duration of the contracts/arrangements/transactions- FOR THE YEAR
  - (d) Salient terms of the contracts or arrangements or transactions including the value, if any:
  - (e) Date(s) of approval by the Board, if any: - 31/03/2022
  - (f) Amount paid as advances, if any: NIL

Form shall be signed by the persons who have signed the Board's report.

For and on behalf of Board of Directors

For Bio-Medica Laboratories Pvt. Ltd.,

Mukesh Mehta  
Director  
DIN: 03187420

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

Pradeep Mehta  
Director  
DIN: 07254802

  
Director.

## NOTICE FOR CALLING ANNUAL GENERAL MEETING

Notice is hereby given that the 8th Annual General Meeting of the Company will be held on 30<sup>th</sup> day, September 2023 at 11.30 AM at the Registered Office of the Company situated at **PLOT-254, SECTOR-F SANWER ROAD -INDORE (M.P.)-452015** to transact the following businesses:-

### A. ORDINARY BUSINESS:

1. To consider and adopt the Audited Financial Statements for the financial year ended 31st March, 2023 and the Reports of the Board of Directors and Auditors thereon and to consider and if thought fit, to pass with modification(s) the following resolution as an Ordinary Resolution:

**"RESOLVED THAT** pursuant to provisions of Section 139, 142 and other applicable provisions of the Companies Act, 2013, if any, read with the Companies (Audit & Auditors) Rules, 2014, **M/S AKSHAY VIJAWAT & CO.**, Chartered Accountants, Firm Registration No.023175C be and are hereby appointed as Statutory Auditors of the company, to hold office from the 9<sup>th</sup> Annual General Meeting till the conclusion of the 13<sup>th</sup> Annual General Meeting at remuneration as may be fixed by the Board of Directors at a later stage

**"RESOLVED THAT** the Directors' Report and the Audited Balance Sheet as on year ended 31st March, 2023 and the Profit and Loss Accounts for the Year ended on 31st March, 2023 along with the Auditors' Report thereon are hereby considered, approved and adopted."

BY ORDER OF THE BOARD

FOR - **BIO MEDICA LABORATORIES PRIVATE LIMITED**

Date: 02/09/2023

Place: INDORE

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director,

For Bio-Medica Laboratories Pvt. Ltd.,



Director.

**FORM NO. MGT 9**  
**EXTRACT OF ANNUAL RETURN**  
As on financial year ended on 31.03.2023

Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company (Management & Administration) Rules, 2014.

I. REGISTRATION & OTHER DETAILS:		
1	CIN	U24230MP2015PTC034576
2	Registration Date	14TH AUGUST 2015
3	Name of the Company	BIO MEDICA LABORATORIES PRIVATE LIMITED
4	Category/Sub-category of the Company	COMPANY LIMITED BY SHARE INDIAN NON-GOVERNMENT COMPANY
5	Address of the Registered office & contact details	PLOT-254, SECTOR-F SANWER ROAD INDORE M.P. 452015
6	Whether listed company	NO
7	Name, Address & contact details of the Registrar & Transfer Agent, if any.	Not Applicable

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY			
(All the business activities contributing 10 % or more of the total turnover of the company shall be stated)			
S. No.	Name and Description of main products / services	NIC Code of the Product/service	% to total turnover of the company
1	MANUFACTURE OF PHARMACEUTICALS, MEDICINE CHEMICAL	2100	100
	BOTANICAL PRODUCTS		
2			


III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES					
SN	Name and address of the Company	CIN/GLN	Holding/ Subsidiary/ Associate	% of shares held	Applicable Section
1					
2					
3					

IV. SHARE HOLDING PATTERN									
(Equity share capital breakup as percentage of total equity)									
(i) Category-wise Share Holding									
Category of Shareholders	No. of Shares held at the beginning of the year [As on 01-April-2022]				No. of Shares held at the end of the year [As on 31-March-2023]				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
<b>A. Promoters</b>									
(1) Indian									
a) Individual/ HUF		100,000	100,000	100.00%		100,000	100,000	100.00%	0.00%
b) Central Govt.			-	0.00%			-	0.00%	0.00%
c) State Govt(s)			-	0.00%			-	0.00%	0.00%
d) Bodies Corp.			-	0.00%			-	0.00%	0.00%
e) Banks / FI			-	0.00%			-	0.00%	0.00%
f) Any other			-	0.00%			-	0.00%	0.00%
<b>Sub Total (A) (1)</b>	-	100,000	100,000	100.00%	-	100,000	100,000	100.00%	0.00%
(2) Foreign									
a) NRI Individuals			-	0.00%			-	0.00%	0.00%
b) Other Individuals			-	0.00%			-	0.00%	0.00%

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,



Director.




c) Bodies Corp.			-	0.00%			-	0.00%	0.00%
d) Any other			-	0.00%			-	0.00%	0.00%
<b>Sub Total (A) (2)</b>	-	-	-	0.00%	-	-	-	0.00%	0.00%
<b>TOTAL (A)</b>	-	100,000	100,000	100.00%	-	100,000	100,000	100.00%	0.00%
<b>B. Public Shareholding</b>									
<b>1. Institutions</b>									
a) Mutual Funds			-	0.00%			-	0.00%	0.00%
b) Banks / FI			-	0.00%			-	0.00%	0.00%
c) Central Govt			-	0.00%			-	0.00%	0.00%
d) State Govt(s)			-	0.00%			-	0.00%	0.00%
e) Venture Capital Funds			-	0.00%			-	0.00%	0.00%
f) Insurance Companies			-	0.00%			-	0.00%	0.00%
g) FIs			-	0.00%			-	0.00%	0.00%
h) Foreign Venture Capital Funds			-	0.00%			-	0.00%	0.00%
i) Others (specify)			-	0.00%			-	0.00%	0.00%
<b>Sub-total (B)(1)-</b>	-	-	-	0.00%	-	-	-	0.00%	0.00%
<b>2. Non-Institutions</b>									
a) Bodies Corp.									
i) Indian			-	0.00%			-	0.00%	0.00%
ii) Overseas			-	0.00%			-	0.00%	0.00%
b) Individuals									
i) Individual shareholders holding nominal share capital upto Rs. 1 lakh			-	0.00%			-	0.00%	0.00%
ii) Individual shareholders holding nominal share capital in excess of Rs 1 lakh			-	0.00%			-	0.00%	0.00%
c) Others (specify)									
Non Resident Indians			-	0.00%			-	0.00%	0.00%
Overseas Corporate Bodies			-	0.00%			-	0.00%	0.00%
Foreign Nationals			-	0.00%			-	0.00%	0.00%
Clearing Members			-	0.00%			-	0.00%	0.00%
Trusts			-	0.00%			-	0.00%	0.00%
Foreign Bodies - D R			-	0.00%			-	0.00%	0.00%
<b>Sub-total (B)(2)-</b>	-	-	-	0.00%	-	-	-	0.00%	0.00%
<b>Total Public (B)</b>	-	-	-	0.00%	-	-	-	0.00%	0.00%
<b>C. Shares held by Custodian for GDRs &amp; ADRs</b>			-	0.00%				0.00%	0.00%
<b>Grand Total (A+B+C)</b>	-	100,000	100,000	100.00%	-	100,000	100,000	100.00%	0.00%


**(ii) Shareholding of Promoter**

SN	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged/ encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged/ encumbered to total shares	

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

1	PRADEEP MEHTA	50,000	50.00%		50,000	50.00%	0.00%
2	MUKESH MEHTA	50,000	50.00%		50,000	50.00%	0.00%
3			0.00%			0.00%	0.00%
4			0.00%			0.00%	0.00%

**(iii) Change in Promoters' Shareholding (please specify, if there is no change)**

SN	Particulars	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
	At the beginning of the year	01/04/2022		100,000	100.00%	100,000	100.00%
	Changes during the year		Transfer	-	0.00%	-	0.00%
					0.00%		0.00%
					0.00%		0.00%
	At the end of the year	31/03/2023		100,000	100.00%	100,000	100.00%

**(iv) Shareholding Pattern of top ten Shareholders**

(Other than Directors, Promoters and Holders of GDRs and ADRs):

SN	For each of the Top 10 shareholders	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
1	Name						
	At the beginning of the year				0.00%		0.00%
	Changes during the year				0.00%		0.00%
	At the end of the year				0.00%		0.00%
2	Name						
	At the beginning of the year				0.00%		0.00%
	Changes during the year				0.00%		0.00%
	At the end of the year				0.00%		0.00%

**(v) Shareholding of Directors and Key Managerial Personnel:**

SN	Shareholding of each Directors and each Key Managerial Personnel	Date	Reason	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
				No. of shares	% of total shares	No. of shares	% of total shares
1	PRADEEP MEHTA						
	At the beginning of the year	01/04/2022		50,000	50.00%	50,000	50.00%
	Changes during the year				0.00%		0.00%
	At the end of the year	31/03/2023		50,000	50.00%	50,000	50.00%
2	MUKESH MEHTA						
	At the beginning of the year	01/04/2022		50,000	50.00%	50,000	50.00%
	Changes during the year				0.00%		0.00%
	At the end of the year	31/03/2023		50,000	50.00%	50,000	50.00%

**V. INDEBTEDNESS**

Indebtedness of the Company including interest outstanding/accrued but not due for payment.

(Amt. Rs.)

Particulars	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
<b>Indebtedness at the beginning of the financial year</b>				
(i) Principal Amount	86,169,838.00	23,434,851.00		109,604,689.00

For Bio-Medica Laboratories Pvt. Ltd.,

*Mukesh*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

*Pradeep*  
Director.



i) Interest due but not paid		-		-
ii) Interest accrued but not due		-		-
<b>Total (i+ii+iii)</b>	<b>86,169,838.00</b>	<b>23,434,851.00</b>	<b>-</b>	<b>109,604,689.00</b>
<b>Change in indebtedness during the financial year</b>				
* Addition	7,491,881.00			7,491,881.00
* Reduction	(4,929,409.00)	(16,100,523.00)		(21,029,932.00)
Net Change	2,562,472.00	(16,100,523.00)	-	(13,538,051.00)
<b>Indebtedness at the end of the financial year</b>				
(i) Principal Amount	88,732,310.00	7,334,328.00		96,066,638.00
ii) Interest due but not paid		-		-
iii) Interest accrued but not due		-		-
<b>Total (i+ii+iii)</b>	<b>88,732,310.00</b>	<b>7,334,328.00</b>	<b>-</b>	<b>96,066,638.00</b>

## VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

### A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

SN.	Particulars of Remuneration	Name of MD/WTOD/ Manager		Total Amount (Rs/Lac)
		Name	Designation	
		Mukesh Mehta	Pradeep Mehta	
		Managing Director	Managing Director	
1	Gross salary			
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	24.00	24.00	48.00
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961			-
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961			-
2	Stock Option			-
3	Sweat Equity			-
	Commission			-
4	- as % of profit			-
	- others, specify			-
5	Others, please specify - Bonus			-
	Total (A)	24.00	24.00	48.00
	Ceiling as per the Act			

### B. Remuneration to other Directors

SN.	Particulars of Remuneration	Name of Directors		Total Amount (Rs/Lac)
1	Independent Directors			
	Fee for attending board committee			-
	Commission			-
	Others, please specify			-
	Total (1)	-	-	-
2	Other Non-Executive Directors			-
	Fee for attending board committee			-
	Commission			-
	Others, please specify			-
	Total (2)	-	-	-
	Total (B)=(1+2)	-	-	-
	Total Managerial Remuneration			48.00
	Overall Ceiling as per the Act			

### C. Remuneration to Key Managerial Personnel other than MD/Manager/WTOD

SN.	Particulars of Remuneration	Name of Key Managerial Personnel	Total
-----	-----------------------------	----------------------------------	-------

For Bio-Medica Laboratories Pvt. Ltd.,

*Mukesh*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

*Pradeep*

Director.



	Name				(Rs/Lac)
	Designation	CEO	CFO	CS	
1	Gross salary				
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961				-
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961				-
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961				-
2	Stock Option				-
3	Sweat Equity				-
	Commission				
4	- as % of profit				-
	- others, specify				-
5	Others, please specify				-
	Total				-

#### VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority (RD / NCLT/ COURT)	Appeal made, if any (give Details)
<b>A. COMPANY</b>					
Penalty					
Punishment					
Compounding					
<b>B. DIRECTORS</b>					
Penalty					
Punishment					
Compounding					
<b>C. OTHER OFFICERS IN DEFAULT</b>					
Penalty					
Punishment					
Compounding					

**Mukesh Mehta**  
Director  
DIN: 03187420

**Pradeep Mehta**  
Director  
DIN: 07254802

For Bio-Medica Laboratories Pvt. Ltd.,

*Mukesh*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

*Pradeep*  
Director.

**DIRECTORS REPORT**

Dear Members,

Your Directors have pleasure in presenting this 8<sup>th</sup> Annual report on the affairs of the Company together with the Audited Statement of Accounts for the year ended on 31<sup>st</sup> March, 2023

**1. Financial Summary or performance of the company:**


( in Rs.)

<b>PARTICULARS</b>	<b>2022-23</b>	<b>2021-22</b>
1.NET SALES	162281784	212252005
2A.OTHER OPERATING INCOME	-	-
2B.OTHER INCOME	492900	2118338
<b>3.TOTAL INCOME(1+2A+2B)</b>	<b>162774684</b>	<b>214370343</b>
A) COST OF MATERIAL CONSUMED	115870739	148843972
B) PURCHASE OF STOCK IN TRADE		21159615
C) CHANGES IN INVENTORIES OF FINISHEDGOODS	(1189241)	(2888281)
D) EMPLOYEE BENIFITS EXPENSES	18123090	17265519
G) OTHER EXPENSES	12393802	11059336
<b>4. TOTAL EXPENSES</b>	<b>145198390</b>	<b>195440161</b>
<b>5. EBDIT(3-4+E+F)</b>	<b>17576294</b>	<b>18930182</b>
6. INTEREST	7732846	7675628
7. DEPRECIATION	4966774	3281483
<b>8.PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX(5-6-7)</b>	<b>4876674</b>	<b>7973070</b>
9.CURRENT TAX & EARLIER TAX	1257074	2109125
10.MAT CREDIT RECEIVABLE	-	-
11.DEFERRED TAX	21014	(26057)
<b>12.NET PROFIT AFTER TAX</b>	<b>3598586</b>	<b>5890002</b>

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director

**\*Previous year figures have been regrouped/ rearranged wherever necessary**

## **2. Operations**

The Company has reported Gross receipt of ₹ 162,281,784/- for the current year as compared to ₹ 212,252,005/- in the previous year. The Net Profit for the year under review amounted to ₹ 35,98,586/- in the current year as compared to Profit of ₹ 58,90,002/- in the previous year.

## **3. Transfer to reserves**

The Company proposes to carrying a total reserve & surplus of ₹ 2,61,33,879 /- including current year's Profit.

## **4. State of Company's Affairs and Future Outlook**

Your directors are taking the best efforts so as to maximize the profits of the Company. During the year Company has made such investments which will give fruitful results in the year to come.

## **5. Disclosure regarding Issue of Equity Shares with Differential Rights: NA**

## **6. Disclosure regarding issue of Employee Stock Options: NA.**


## **7. Disclosure regarding issue of Sweat Equity Shares: NA**

## **8. Dividend**


Your directors do not recommend any dividend for financial period 2022-23.

## **9. Extract of Annual Return**

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,



Director.



The extract of Annual Return, in format MGT -9, for the Financial Year 2022-23 has been enclosed with this report.

**10. Material Changes between the date of the Board report and end of financial year :-**

There have been no material changes and commitments, if any, affecting the financial position of the Company which have occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report.

**11. Significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future:**

During the year under review there has been no such significant and material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future.

**12. Subsidiary Company:**

As on March 31, 2023, the Company does not have any subsidiary.

**13. Statutory Auditor & Audit Report:**

M/s. Lunawat & Somani, Chartered Accountants, statutory auditors of the Company having Firm Registration Number 012609C has resigned from this Annual General Meeting and M/s Akshay Vijawat & Co. Chartered Accountants, appoint statutory auditors of the Company having Firm Registration Number 023175C hold office from 9<sup>th</sup> AGM until the conclusion of the 13<sup>th</sup> Annual General Meeting subject to the ratification of the members at every general meeting. Further, the report of the Statutory Auditors alongwith notes to Schedules is enclosed to this report. The observations made in the Auditors' Report are self-explanatory and therefore do not call for any further comments.

**14. Change in the nature/Name of business :-**

There is no change in the nature or name of the business of the company

**15. Corporate Social Responsibility:**

The Company is not required to constitute a Corporate Social Responsibility Committee as it does not fall within purview of Section 135(1) of the Companies Act, 2013 and hence it is not required to formulate policy on corporate social responsibility.


**16. Number of meeting of the Board:**

During the year 2022-23, the Board of Directors met Six times viz. on 12/06/2022; 02/09/2022; 29/09/2022, 02/12/2022, 08/02/2023 and 31/03/2023.

**17. Directors' Responsibility Statement:**

Pursuant to the requirement under section 134(3) (C) of the Companies Act, 2013 with respect to Directors' Responsibility Statement, it is hereby confirmed that:

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

(i) In the preparation of the annual accounts for the financial year ended 31<sup>st</sup> March, 2023, the applicable accounting standards had been followed along with proper explanation relating to material departures;

(ii) The directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2023 and of the profit and loss of the company for that period;

(iii) The directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(iv) The directors had prepared the annual accounts on a going concern basis.

(vi) The directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

**18. Declaration by Independent Directors:**

The Company was not required to appoint Independent Directors under Section 149(4) and Rule 4 of the Companies (Appointment and Qualification of Directors) Rules, 2014 hence no declaration has been obtained.

**19. Company's policy on directors' appointment and remuneration including criteria for determining qualifications, positive attributes, independence of a director and other matters provided under sub-section (3) of section 178;**

The Company, being a Private Limited Company was not required to constitute a Nomination and Remuneration Committee under Section 178(1) of the Companies Act, 2013 and Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Stakeholders Relationship Committee under Section 178(5) of the Companies Act, 2013.

**15. Particulars of loans, guarantees or investments under section 186:**

During the year under review, the Company has not advanced any loans/ given guarantees/ made investments.

**16. Particulars of Employee:**

None of the employee has received remuneration exceeding the limit as stated in rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

**17. Voluntary Revision of Financial Statements or Board's Report: NA**

**18. Statement in Respect of Adequacy of Internal Financial Control with Reference to the Financial Statements: NA**

**19. Secretarial Audit Report: NA**

**20. Re-appointment of Independent Auditor: NA**


**21. Corporate Social Responsibility (CSR) Policy: NA**

**22. Audit Committee: NA**

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.



**23. Managerial remuneration:**

During the year Company has paid amount of Rs. 48,00,000/- as Managerial Remuneration (Including Bonus) to the Directors of the company.

**24. Particulars of contracts or arrangements with related parties: -**

The particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act 2013 for the Financial Year 2022-23 in the prescribed format, AOC 2 has been enclosed with the report.

**25. Details of Directors and Key Managerial Personnel**

The Board consists of the following directors namely:-

DIN NO	NAME	DESIGNATION	DATE OF APPOINTMENT	DATE OF RESIGNATION
07254802	PRADEEP MEHTA	Director	14/08/2015	NA
03187420	MUKESH MEHTA	Director	14/08/2015	NA

**26. Risk management policy:-**

It may pleased be noted that as per the applicable requirement of Companies Act, 2013 a risk management policy of the Company is developed and implemented and Board reviews the same periodically for creating and protecting the Shareholder's value by minimizing threats or losses and to identify and provide a framework that enables future activities of a Company to take place in a consistent and controlled manner.

**27. Details on conservation of energy, technology absorption, foreign exchange earnings and outgo:-**

Information as per Section 134(3)(m) of the Companies Act, 2013, read with Companies (Accounts) Rules, 2014 and forming part of the Directors' Report to the members for the year ended 31st March, 2023.

- 1. Conservation of Energy:** - The activities carried out by the Company are not power intensive and the cost of the energy is insignificant. The Company is not utilizing alternate sources of energy.
- 2. Technical Absorption:-** The Company has not imported any technology during the year. There is no specific amount spent for research and development.

**28. Statement Indicating the Manner in which Formal Annual Evaluation has been made by the Board of its own Performance, its Directors, and that of its Committees: NA****29. Nomination & Remuneration Committee Policy: NA**


For Bio-Medica Laboratories Pvt. Ltd.,

**30. Disclosure on Establishment of a Vigil Mechanism: NA**


Director.

**31. Corporate Governance: NA**

For Bio-Medica Laboratories Pvt. Ltd.,



Director.



**32. Formal evaluation by board of its own performance:-**

It may please be noted that the Statement in respect of Formal Evaluation by the Board of its own performance and that of its committees and individual directors is not applicable to the Company.

**33. Internal Financial Controls**

The company is having adequate internal financial controls with reference to the financial statements in terms of Section 134 (3) (g) of Companies Act, 2013 read with Rule 8 (5) (viii) of Companies (Accounts) Rules, 2014.

**Acknowledgement:**

Your Directors wish to place on record their sincere appreciation and gratitude for the valuable support and co-operation received from the Customers and Suppliers, various Financial Institutions, Banks, Government Authorities, Auditors and Shareholders during the year under review. Your Directors wish to place on record their deep sense of appreciation for the devoted services of the Executives, Staff and Workers of the Company for its success Your Directors also thank the Central and State Governments, and other statutory authorities for their continued support.

**For and on behalf of board of directors**

For Bio-Medica Laboratories Pvt. Ltd.,

**Mukesh Mehta**  
Director  
DIN: 03187420

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

**Pradeep Mehta**  
Director  
DIN: 07254802

  
Director.

**Date: 02.09.2023**

**Place: Ipore**



**INDEPENDENT AUDITOR'S REPORT**

To  
The Members, Bio Medica Laboratories Private Limited  
(CIN:U24230MP2015PTC034576)

**Report on the financial statements**

**Opinion**

We have audited the accompanying Standalone financial statements Bio Medica Laboratories Private Limited which comprises the Balance Sheet as at March 31, 2023, and the Statement of Profit and Loss for the year then ended, statement of cash flows and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, and Profit for the year ended on that date.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

**Other information**

The Company's Board of Directors is responsible for the other information. The other information obtained at the date of this auditor's report is information included in the Annual report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is not material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.





## **Responsibility of Management for the Standalone Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position and financial performance of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

## **Auditor's Responsibility for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.





We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Report on Other Legal and Regulatory Requirements**

1 The provisions of the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, is not applicable to the company, as it is a Small company as per section 2(85), having paid up share capital of less than Rs. 4.00 crores and turnover less than Rs. 40.00 crores during the year.

2.) As required by Section 143(3) of the Act, we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

c) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report are in agreement with the books of account.

d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

e) On the basis of the written representations received from the directors as on 31st March, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.

(f) Reporting on the adequacy with respect to the internal financial controls over financial reporting of the company and the operating effectiveness of such controls are not applicable to the company. Since the Company is a small company and its turnover as per last audited financial statements is less than Rs.50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs.25 Crores.

(g) The Company being a private limited company, the other matters to be included in the Auditor's Report in accordance with the requirements of section 197 (16) of the Act, as amended, in respect of whether the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act is not applicable

(h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

(i) The Company does not have any pending litigations which would impact its financial position.

(ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.



(iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company

iv) Management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts,

(a) No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) No funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries, and

(c) Based on the audit procedures adopted by us, nothing has come to our notice that has caused us to believe that the representations made by the Management under sub clause (a) and (b) above, contain any material misstatement.

v. The Company has not declared or paid any dividends during the year and accordingly reporting on the compliance with section 123 of the Companies Act, 2013 is not applicable for the year under consideration.

vi. Proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 for maintaining books of account using software which has a feature of audit trail (edit log) facility is applicable to the Company with effect from April 01, 2023, and accordingly, reporting under Rule 11(g) of Companies (Audit and Auditors) Rule, 2014 is not applicable for the financial year ended March 31, 2023.

For Lunawat & Somani  
Chartered Accountants  
FRN: 012609C



CA. Gaurav Lunawat  
(Partner)  
Membership No.:405423  
UDIN: 23405423BHACOC6090



Place: Indore  
Date: 02.09.23



## NOTES TO Financial Statements:

For the year ended 31st March, 2023

### A CORPORATE INFORMATION:

Bio Medica Laboratories Private Limited is a private limited company incorporated and domiciled in India and governed by the Companies Act, 2013 ("Act"). The Company's registered office is situated at 254, Sector F, Sanwer Road, Indore, (M.P.), 452001.

### B SIGNIFICANT ACCOUNTING POLICIES:

#### a) Basis of preparation

These financial statements have been prepared to comply in all material aspects with applicable accounting principles in India, the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Act') read with applicable Rules, the provisions of the Act (to the extent notified) and other accounting principles generally accepted in India, to the extent applicable. The financial statements have been prepared under the historical cost convention, on the accounting principles of going concern. All expenses and income to the extent ascertainable with reasonable certainty are accounted for on accrual basis. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.

#### b) Revenue recognition

Revenue from sale of goods is recognized when all the significant risks and rewards of ownership in the goods are transferred to the buyer as per the terms of the contract, the Company retains no effective control of the goods transferred to a degree usually associated with ownership and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of goods. Sales are recognized net of trade discounts, rebates, goods and services tax and excise duties (on goods manufactured and outsourced).

#### c) Borrowing Costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized in profit or loss in the period in which they are incurred.

#### d) Property, plants and equipment

The cost of an item of property, plant and equipment should be recognized as an asset if, and only if:

(a) It is probable that future economic benefits associated with the it will flow to the enterprise; and

(b) The cost of the item can be measured reliably

Property, plant and equipment are stated at cost, net of recoverable taxes, trade discount and rebates less accumulated depreciation and impairment losses, if any. Such cost includes purchase price, borrowing cost and any cost directly attributable to bringing the assets to its working condition for its intended use.

Losses arising from the retirement of, and gains or losses arising from disposal of tangible assets which are carried at cost are recognized in the Statement of Profit and Loss.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the entity and the cost can be measured reliably.

For Bio-Medica Laboratories Pvt. Ltd.

*Mukul*  
Director

For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*  
Director

Director





#### e) Depreciation

Depreciation is provided on the written down value method and as per Schedule II to the Companies Act, 2013.

The Company has adopted estimated useful life of fixed assets as stipulated by Schedule II to the Companies Act, 2013 in case of assets purchased during the year and depreciation is being provided on pro-rata basis from the date of acquisition/commissioning if any.

#### f) Inventories

Items of inventories (if available) are measured at lower of cost and net realizable value after providing for obsolescence, if any. Cost is determined on first-in-first out basis.

Cost of inventories comprises of cost of purchase, cost of conversion and other costs including manufacturing overheads net of recoverable taxes incurred in bringing them to their respective present location and condition.

Net Realizable Value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

#### g) Earnings per share

Basic earnings per share are calculated by dividing the net profit for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period. (Amount in RS Hundreds)

Particulars	2023-23	2021-22
Profit for the year	35985.86	58900.02
Weighted average number of equity shares outstanding	100000	100000
Earnings Per Share (In Rs.) - Basic (Face value of Re. 10 per share)	35.99	58.90
Earnings Per Share (In Rs.) - Diluted (Face value of Re. 10 per share)	35.99	58.90

#### h) Use of estimates

The preparation of the financial statements in conformity with the generally accepted accounting principles requires that the management makes estimates and assumptions that affect the reported amounts of assets and liabilities, and the reported amounts of revenue and expenses during the reported period. Actual results could differ from those estimates.

#### i) Tax Expenses

The tax expense for the period comprises current and deferred tax. Tax is recognized in Statement of Profit and Loss. As per information & explanation provided by the management, the company has not made any provision for deferred tax assets/liabilities.

Current tax: Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates and laws that are enacted or substantively enacted at the Balance Sheet date.



For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*

Director.

Deferred tax: Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit.

Deferred tax liabilities and assets are measured at the tax rates that are expected to apply in the period in which the liability is settled or the assets realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of reporting period.

The company has not recognized deferred tax assets as there is no virtual certainty supported by convincing evidence that sufficient future taxable income will be available against which such deferred tax assets can be realized.

j) Transactions in foreign currencies are recorded at the exchange rate prevailing on the date of the transaction. Monetary assets and liabilities other than forward contracts, outstanding at the Balance Sheet date are translated at the applicable exchange rates prevailing at the said date. The exchange gain/loss arising during the year are adjusted to the Statement of Profit and Loss.


**k) Related Party Disclosures:**

As per Accounting Standard 18, the disclosures of transactions with the related parties are given below:

List of related parties where control exists and related parties with whom transactions have taken place and relationships:

Sr. No.	Name of the Related Party	Relationship
1	Mukesh Mehta	Key Managerial Personnel
2	Pradeep Mehta	Key Managerial Personnel
3	Akron Remedies	Relative of KMP
4	Mehta Sales Corporation	Relative of KMP
5	Hospara Healthcare	Relative of KMP (Previous Year)
6	Tara Mehta	Relative of KMP
7	Garima Mehta	Relative of KMP
8	Anju Mehta	Relative of KMP
9	Lokesh Mehta	Relative of KMP
10	Bio Medica Parenterals	Relative of KMP

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.





(Amount in Rs Hundreds)

				Balances at Year End	
Particulars	Relationship	2022-23	2021-22	2023-23	2021-22
<b>I. Net Loans &amp; Advances</b>					
<b>Taken/(Returned) :</b>					
Mukesh Mehta	Key Managerial Personnel	NIL	37557.65	67475.76 Cr	186724.62 Cr
		-125000.00	-4141.90		
Pradeep Mehta	Key Managerial Personnel	10766.39	28285.34	5867.53	47623.9 Cr
		-55000	15651.71		
<b>II. Sales :</b>					
Hospara Healthcare	Relative of KMP (Previous Year)	-	2809.94	-	809.94 Dr
<b>III Purchase:</b>					
Mehta Sales Corp	Relative of KMP	-	45677.27		33017.27 CR
Hospara Health Care	Relative of KMP (Previous Year)	-	49545.56	-	-
<b>IV Salary &amp; Bonus:</b>					
Tara Mehta	Relative of KMP	4550.00	3900.00	248.42	-
Garima Mehta	Relative of KMP	3600.00	2860.00	-	-
Anju Mehta	Relative of KMP	3600.00	2860.00	-	-
Lokesh Mehta	Relative of KMP	9600.00	9600.00	500.00	-
<b>V Interest:</b>					
Mukesh Mehta	Key Managerial Personnel	7188.93	18754.52	-	-
Pradeep Mehta	Key Managerial Personnel	3096.54	5408.54	-	-
<b>VI Supervision Charges:</b>					
BIO Medica prenterals	Relative of KMP	1200.00	1200.00	2180.79 Cr	2280.00 Cr
<b>VIII Director's remuneration:</b>					
Mukesh Mehta	Key Managerial Personnel	24000.00	24000.00	-	-
Pradeep Mehta	Key Managerial Personnel	24000.00	24000.00	115.20 Cr	72.25 Cr

For Bio-Medica Laboratories Pvt. Ltd.,

  
 Director.

For Bio-Medica Laboratories Pvt. Ltd.,

  
 Director.




#### **l) Employee Benefit Expenses:**

Short-term employee benefits are employee benefits (other than termination benefits) which fall due wholly within twelve months after the end of the period in which the employees render the related service. Contributions of eligible employees under provident and other fund and short term employee benefits are recognised in the statement of Profit and Loss Account.

#### **m) Provisions & Contingent Liabilities :**

- Provision is recognized when:
  - (a) the enterprise has a present obligation as a result of a past event;
  - (b) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and
  - (c) A reliable estimate can be made of the amount of the obligation.
- Contingent liability is disclosed unless the possibility of an outflow of resources embodying economic benefits is remote.

As per the explanations given to us and as per the records maintained by the company, there is no contingent liability as at 31st March 2023.

n) Value of import on CIF basis by the company during the year Rs. 29391.63/- (Amount in Rs Hundred)

- Expenditure in Foreign currency during the financial year on account of royalty, Know-how, Professional consultancy fees, interest and other charges, Rs. NIL
- Amount remitted during the year in foreign currencies on account of dividend Rs. NIL
- Earning in foreign Exchange, Rs. NIL

o) Following are the additional disclosures required as per Schedule III to the Companies Act, 2013 vide Notification dated March 24, 2021;

1. Details of Benami Property held:

There are no proceedings which have been initiated or pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder.

2. Willful Defaulter: The Company has not been declared as Willful Defaulter by any Bank or Financial Institution or other Lender.

3. Relationship with Struck off Companies: During the year, as per information available with the company, the Company does not have any transactions with the companies struck off under section 248 of Companies Act, 2013 or section 560 of Companies Act, 1956.

4. Compliance with number of layers of companies: The Company has complied with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017.

5. Utilisation of Borrowed funds and share premium: During the financial year ended 31st March 2023, company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the intermediary shall (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate



For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*

Director

Beneficiaries) or (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

6. Undisclosed Income: The Company does not have any transactions not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961). Also, there are nil previously unrecorded income and related assets.

7. Details of Crypto Currency or Virtual Currency: The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

8. Title deeds, Capital work in progress (CWIP) and Intangible asset:  
The Company does not own any immovable property. The Company does not have any CWIP and Intangible asset under development. The Company has not revalued its Property, Plant and Equipment during the year as well as in previous year.

9. Registration of charges or satisfaction with Registrar of Companies: There are no charges or satisfactions which are yet to be registered with the Registrar of Companies beyond the statutory period, except the charge satisfaction with SIDBI ( original sanction Rs 13000.00, Rs one crore thirty lacs) which is not yet satisfied for the loan squared off during the year and charge creation/modification has not been done within statutory time period for the three long/short term working capital term loans for Rs. 50000.00 (Fifty lacs), Rs. 60000.00 (sixty lacs) and Rs. 70000.00 (Seventy lacs) taken from kotak Mahindra bank in July'22.

10. Compliance with approved Scheme(s) of Arrangements: No Scheme of Arrangements has been approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013.

11. Corporate Social Responsibility (CSR) : The company is not covered under section 135 of the companies Act 2013.

12. Borrowing from bank: The Company has used the borrowings from banks and financial institutions for the specific purpose for which it was taken as at the reporting date.

13. The Company has borrowings from banks or financial institutions on the basis of security of current assets however as it is an overdraft and term loan limit and therefore company does not required to submit quarterly returns or statements of current assets to the bank as per the terms of sanction.

14. Key Accounting Ratios: As follows:

Particulars	Numerator	Denominator	Ratio 31.03.23	Numerator	Denominator	Ratio 31.03.22	% Change	Remarks
(a) Current Ratio	907536.37	1015655.39	0.89	1024918.39	1098106.59	0.93	-12.05	-
(b) Debt-Equity Ratio	467047.60	271338.79	1.72	411992.39	235352.94	1.75	-1.71	-
(c) Debt Service Coverage Ratio	175762.94	221368.67	0.79	189301.81	160421.90	1.18	-33.05	Due to increase in borrowings.
(d) Return on Equity Ratio	35985.86	10000.00	3.60	58900.02	10000.00	5.89	-38.88	Due to decrease in sales and profit.
(e) Inventory turnover ratio	1158707.39	311478.30	3.72	1700035.87	264408.95	6.43	-42.15	Due to decrease in purchases and consumption during the year.
(f) Trade Receivables turnover ratio	1622817.84	476001.68	3.41	2122520.05	422545.51	5.02	-32.07	Due to decrease in sales in the current year -



For Bio-Medica Laboratories Pvt. Ltd.,

*Hulsi*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*

Director.



(g) Trade payables turnover ratio	1304242.18	420703.55	3.10	1607864.57	360664.31	4.46	-30.49	Due to decrease in credit purchase during the year
(h) Net capital turnover ratio	1622817.84	-108019.02	-15.02	2122520.05	-73188.20	-29.00	-48.21	Due to decrease in sales in the current year.
(i) Net profit ratio	35985.86	1622817.84	0.02	58900.02	2122520.05	0.03	-33.33	Due to Decrease in sales and profit during the year
(j) Return on Capital employed	126095.20	738386.39	0.17	156486.98	647345.33	0.24	-29.36	Due to decrease in net profit during the year
(k) Return on investment*	NA	NA	NA	NA	NA	NA	NA	

\*Company does not have any investments.


Element of Ratios:	Numerator	Denominator
Current Ratio	Current Assets	Current Liabilities
Debt-Equity Ratio	Total Debt (Long term)	Total Equity and Reserves
Debt Service Coverage Ratio	Earning Before interest, Tax and depreciation	Interest and Repayment of non current borrowings
Return on Equity Ratio	Net profit after tax	Average Equity
Inventory turnover ratio	Cost of good sold	Average Inventory
Trade Receivables turnover ratio	Revenue from operation	Average Trade Receivables
Trade payables turnover ratio	Total Purchases	Average Trade Payables
Net capital turnover ratio	Revenue from operation	Working Capital
Net profit ratio	Net profit after tax	Revenue from operation
Return on Capital employed	Earning Before interest and Tax	Capital Employed (Total Assets-Current Liability)

p)The financial statements have been prepared and presented in accordance with the amended Division I of Schedule III to the Companies Act, 2013 issued vide notification dated March 24, 2021 (the "Notification"). Certain category of assets and liabilities have been regrouped / reclassified based on the requirements of the notification. Accordingly, previous year's figures have been regrouped / reclassified wherever required to make their classification comparable with that of the current year.

For Lunawat & Somani  
Chartered Accountants  
(Firm Registration No. : 012609C)

CA. Gaurav Lunawat  
(Partner)  
(Membership No.: 405423)  
UDIN: 23405423BHACOC6090

For Bio Medica Laboratories Private Limited  
For Bio-Medica Laboratories Pvt. Ltd., For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

Director

MUKESH MEHTA  
DIN:03187420

  
Director.

Director

PRADEEP MEHTA  
DIN:07254802

Place: Indore

Date: 02.09.23



BIO MEDICA LABORATORIES PRIVATE LIMITED				
(Balance Sheet As on 31 March 2023)				
(CIN: U24230MP2015PTC034576)				
(Amount in Rs. hundred)				
Particulars	Note No.	As at 31 March, 2023	As at 31 March, 2022	
<b>A EQUITY &amp; LIABILITIES</b>				
1 Shareholder's Funds				
(a) Share Capital	A	10000.00	10000.00	
(b) Reserves & Surplus	B	261338.79	225352.94	
(c) Money Received Against Share Warrant		-	-	
2 Share Application Money Pending Allotment				
3 Non-Current Liabilities				
(a) Long-Term Borrowings	C	467047.60	411992.39	
(b) Deferred Tax Liabilities (Net)		-	-	
(c) Other Long Term Liabilities		-	-	
(d) Long-Term Provisions		-	-	
4 Current Liabilities				
(a) Short-Term Borrowings	D	493618.78	684054.50	
(b) Trade Payables	E	479798.04	361609.06	
(c) Other Current Liabilities	F	29667.83	31351.78	
(d) Short-Term Provisions	G	12570.74	21091.25	
<b>B TOTAL</b>		<b>1754041.78</b>	<b>1745451.92</b>	
<b>1 ASSETS</b>				
Non-Current Assets				
(a) Property, Plants & Equipment and intangible Assets				
(i) Property, Plant and Equipment	H	833146.94	709855.47	
(ii) Intangible Assets		-	-	
(iii) Capital Work-in-Progress		-	-	
(iv) Intangible Assets Under Development		-	-	
(b) Non-Current Investments		-	-	
(c) Deferred Tax Assets (net)	I	2597.79	2807.93	
(d) Long-Term Loans And Advances		-	-	
2 (e) Other Non-Current Assets		12660.61	7870.12	
Current Assets				
(a) Current Investments	J	390191.90	232764.70	
(b) Inventories	K	407312.10	544691.26	
(c) Trade Receivables	L	19829.41	152819.55	
(d) Cash and Cash Equivalents	M	24063.62	31114.65	
(e) Short-Term Loans And Advances	N	66209.35	63328.24	
(f) Other Current Assets		-	-	
<b>TOTAL</b>		<b>1754041.78</b>	<b>1745451.92</b>	
Significant Accounting Policies	A to N			

As per our report of even date

For Lunawat & Sonani

Chartered Accountants  
FIRM: 012699C

  
CA Gaurav Lunawat  
Partner

M. No. 403423

UTIN: 23405423BHACOC6090

Date: 02.09.23

Place: Indore

For and on behalf of The Board of Directors

For Bio-Medica Laboratories Pvt. Ltd.,

  
Mukesh Mehta  
Director  
DIN: 03187420

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

Pradip Mehta  
Director  
DIN: 07254802

BIO MEDICA LABORATORIES PRIVATE LIMITED				
( Statement of Profit & loss for the year ended 31st March 2023)				
(CIN:U24230MP2015PTC034576)				
(Amount in Rs. hundred)				
Particulars		Note No.	As at 31 March, 2023	As at 31 March, 2022
A	CONTINUING OPERATIONS			
1	Revenue from Operations (Gross)	O	16,22,817.84	2122520.05
2	Other Income	P	4,929.00	21183.38
3	Total Income (1 + 2)		16,27,746.84	2143703.43
4	Expenses:			0.00
	(a) Cost of Materials Consumed	Q	11,58,707.39	1488430.72
	(b) Purchases of Stock-in-Trade		-	211596.15
	(c) Change in Inventories of Finished Goods	R	(11,892.41)	-28882.81
	Work-in-Progress and Stock-in-Trade(Increase in Stock)			0.00
	(d) Employee Benefits Expenses	S	1,81,230.90	172655.19
	(e) Finance Costs	T	77,328.46	76756.28
	(f) Depreciation and Amortization Expense	H	49,667.74	32814.83
	(g) Other Expenses	U	1,23,938.02	110593.36
	Total expenses		15,78,980.10	2063972.73
5	Profit before exceptional and Extraordinary items and Tax	(3 - 4)	48,766.74	79730.70
6	Exceptional Items		-	-
7	Profit before extraordinary items and Tax (5-6)		48,766.74	79730.70
8	Extraordinary Items		-	-
9	Profit before Tax (7-8)		48,766.74	79730.70
10	Tax Expense:			
	(1) Current Tax		12,570.74	21,001.24
	(2) Deferred Tax		210.14	(260.57)
11	Profit(loss) for the period from continuing operations (7-8)		35,985.86	58,900.02
12	Profit(loss) from discontinuing operations		-	-
13	Tax expense of discontinuing operations		-	-
14	Profit(loss) from discontinuing operations (after tax) (XI + XIV)		-	-
15	Profit(loss) for the period (XI - XIV)		35,985.86	58,900.02
	Earning Per Equity Share			
	Basic (Face value of Rs. 10 each)	(In Rs.)	35.99	58.90
	Diluted (Face value of Rs. 10 each)	(In Rs.)	35.99	58.90
	Significant Accounting Policies	a to u		
The accompanying notes are an integral part of these financial statements				
As per our report of even date		For Bio-Medica Laboratories Pvt. Ltd.		
For Laxmat & Sonani		For and on behalf of The Board of Directors		
Chartered Accountants		For Bio-Medica Laboratories Pvt. Ltd.,		
UDIN: 242509C		Director.		
CA Gaurav Lunawat		Director.		
Partner		Director.		
M. No.405423		Director.		
UDIN: 2340542388HACOC0060		Director.		
Date: 02.09.23		Director.		
Place: Indore		Director.		

**BIO MEDICA LABORATORIES PRIVATE LIMITED**

Notes Forming Part of Balance Sheet

**Note - A**

**Share Capital**

Particulars	2022-23	2021-22
Authorized Capital ( 100000 Shares of 10 each)	10,000.00	10,000.00
Issued Subscribed & Paid Up Capital	-	-
(100000 equity share of Rs. 10/- each fully paidup)	10,000.00	10,000.00
<b>Total</b>	<b>10,000.00</b>	<b>10,000.00</b>

1) Reconciliation of the shares outstanding at the beginning and at the end of the reporting period:

Particulars	2022-23	2021-22
	No. of Shares	No. of Shares
Equity shares at the beginning of the year	100,000	100,000
Issued during the period	-	-
Equity shares at the end of the year	100,000	100,000

2) Details of the shareholders holding more than 5% in a company

Particulars	2022-23	2021-22
	No. of Shares	No. of Shares
Pradeep Mehta	50,000	50,000
Mukesh Mehta	50,000	50,000

**3) Terms & Rights attached to equity shares**

- a) The Company has only one class of equity shares having a per value of Rs.10/- each, fully paid up.  
b) Each holder of equity share is entitled to one vote per share.  
c) The company declares and pays dividends in Indian rupees. The dividend proposed by the  
d) In the event of liquidation of the company, the holders of equity shares will be entitled to

(4) Shareholding of Promoters & % of change during the Year

Share s held Prom oters at the end of the year	Figures as at the end of previous reporting period			Figures as at the end of previous reporting period		
	No. of Shares held	% of total shares	% Change	No. of Shares held	% of total shares	% Change
Pradeep Mehta	50,000	50.00	-	50,000	50.00	-
Mukesh Mehta	50,000	50.00	-	50,000	50.00	-

For Bio-Medica Laboratories Pvt. Ltd.,

*Mukesh*  
Director,

For Bio-Medica Laboratories Pvt. Ltd.,

*Pradeep*





**Note - B****Reserves & Surplus**

Particulars	2022-23	2021-22
<b>Retained Earnings/ Surplus:</b>		
Balance as per Last Financial Statement	2,25,352.94	1,66,452.92
Add: Profit/(Loss) During the Year	35,985.86	58,900.02
<b>Total</b>	<b>2,61,338.79</b>	<b>2,25,352.94</b>

**Note - C****Long Term Borrowings**

Particulars	2022-23	2021-22
<b>Secured Loan</b>		
From Banks and Financial Institutions (Term Loan)	4,67,047.60	4,11,592.39
From NBFCs	-	-
<b>Total</b>	<b>4,67,047.60</b>	<b>4,11,592.39</b>

**Terms & Conditions of Term Loans:****ICICI BANK (SANCTION 5.10 LAC)**

Repayment : Repayable in 60 equal monthly installments of Rs 10777/- Each from May 2019.

Security: Secured by Hypothecation of motor Vehicle acquired out of this loan and personal guarantee of Directors

Rate of Interest : Interest @ 9.75% Per annum.

**Kotak Bank ( Sanction 30.00 Lac)**

Repayment : Repayable in 60 equal monthly installments of Rs 63152/- Each from DEC 2019.

Security: Secured by Hypothecation of plant & machinery acquired out of this loan and other fixed assets of the company and personal guarantee of directors.

Rate of Interest : Interest @ 9.60% Per annum.

**Kotak Bank ( Sanction 35.00 Lac)**

Repayment : Repayable in 60 equal monthly installments of Rs 69646/-(rephased) each from Jun 2020.

Security: Secured by Hypothecation of plant & machinery acquired out of this loan and other fixed assets of the company and personal guarantee of directors.

Rate of Interest : Interest @ 9.60% Per annum.

**Kotak Bank ( Sanction 102.5 Lac)**

Repayment : Repayable in 120 equal monthly installments of Rs 134889/- Each, started from DEC 2019.

Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors.

Rate of Interest : Interest @ 9.90% Per annum.

**ICICI Bank loan (Sanction 3.90 Lac)**

Repayment : Repayable in 36 equal monthly installments of Rs 12744/- Each from Sept. 2020.

Security: Secured by Hypothecation/ Mortgage of motor Vehicle acquired out of this loan and personal guarantee of Directors

Rate of Interest : Interest @ 10.70% Per annum.

**Kotak Lap (Sanction 125.00 Lac)**

Repayment : Repayable in 120 equal monthly installments of Rs 151660/- Each, started from FEB 2022.

Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors.

Rate of Interest : Interest @ 8% Per annum.

**Kotak Machinery Loan (Sanction 30.00 Lac)**

Repayment : Repayable in 36 equal monthly installments of Rs 95150/- Each, started from FEB 2022.

Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors.

Rate of Interest : Interest @ 8% Per annum.

**Kotak MSME (Sanction 4882000)**

Repayment : Repayable in 48 equal monthly installments of Rs 152984/- Each, started from August 2022 after moratorium of 12 Months.

Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors.

Rate of Interest : Interest @ 8% Per annum.

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*

Director.

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*  
Director.



SIDBI Loan (Sanction Rs. 130000.00)

Repayment: Repayable in 1-17th installments of Rs 720000 and 18th installment of Rs 760000/- Each, plus interest due, started from Aug 2022

Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors

Rate of Interest: Interest @5%PA

SIDBI Loan (Sanction Rs. 70000.00)

Repayment: Repayable in 1-29th installments of Rs 230000 and 30th installment of Rs 330000/- Each, plus interest due, started from March 22

Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors

Rate of Interest: Interest @5%PA

Kotak Lap (Sanction 150000.00)

Repayment: Repayable in 120 equal monthly installments of Rs 177271/- Each, started from Oct 2022

Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors

Rate of Interest: Interest = Repo rate plus spread 3.4 i.e. 7.4 % pa

Kotak Loan (Sanction 60 Lakh)

Repayment: Repayable in 60 months (incl 24 Months Moratorium). Equal monthly installments shall start after the end of moratorium, started from Oct 2022

Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors (Existing security of previous loans)

Rate of Interest: Interest = EBLR plus spread 1% i.e. 8.4 % pa (Floating)

Kotak Loan (Sanction 70 Lakh)

Repayment: Repayable in 84 equal monthly installments of Rs 111914/- Each, started from Dec 2022

Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors (Existing security of previous loans)

Rate of Interest: Interest = 8.80 % pa (Floating)


Kotak Loan (Sanction 50 Lakh)

Repayment: Repayable in 36 equal monthly installments of Rs 158534/- Each, started from Dec 2022


Security: Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee of directors

Rate of Interest: Interest = 8.80 % pa (Floating)

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.



**Note - D****Short-Term Borrowings**

Particulars	2022-23	2021-22
<b>Working Capital Loan: (Secured)</b>		
From Banks	299,933.15	280,069.55
<b>Other Loans from related party (Unsecured):</b>		
Current Maturity of Long Term Borrowings	73,343.28	234,348.51
	120,342.35	169,636.44
<b>Total</b>	<b>493,618.78</b>	<b>684,054.50</b>

Working Capital Bank loan is repayable on demand and primarily secured by hypothecation of stock and book debt And by personal guarantee of directors, bearing interest @9.35% Per annum. Interest for Rs. 301340/- is paid during the year.

Loans repayable on demand being Working Capital facilities from Banks (both fund based and non-fund based) are secured by first pari passu charge by way of hypothecation of stocks of finished goods, raw materials, chemicals, stores, other materials including those in transit, book debts both present and future and the charge on fixed assets of the company.

Other Loans are unsecured and repayable on demand and bearing interest @12 % Per annum.

**Note - E****Trade Payables**

Particulars	2022-23	2021-22
Micro Small & Medium Enterprises	31,189.82	55,664.95
Others	448,608.22	305,944.11
<b>Total</b>	<b>479,798.04</b>	<b>361,609.06</b>

Disclosure of payable to vendors as defined under the "Micro, Small and Medium Enterprise Development Act,

**Trade Payables ageing schedule: As at 31st March, 2023**

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	31,189.82	-	-	-	31,189.82
(ii) Others	448,608.22	3,640.83	255.70	692.00	448,608.22
(iii) Disputed dues-MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-

**Trade Payables ageing schedule: As at 31st March, 2022**

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	55,664.95	-	-	-	55,664.95
(ii) Others	304,751.64	500.47	692.00	-	305,944.11
(iii) Disputed dues-MSME	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-

For Bio-Medica Laboratories Pvt. Ltd.,

*Mukul*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*  
Director.





**Note - F****Other Current Liabilities**

Particulars	2022-23	2021-22
Statutory Dues Payable	3,854.56	7,039.37
Advance from customers	9,824.70	11,196.16
<b>Other Provisions &amp; Payables :</b>		
Other Provisions	13,030.99	-
Creditors for Capital Goods	329.54	1,284.79
Creditors for Expenses	2,628.05	11,831.46
<b>Total</b>	<b>29,667.83</b>	<b>31,351.78</b>

**Note - G****Short-Term Provisions**

Particulars	2022-23	2021-22
Provision for Income Tax	12,570.74	21,091.25
<b>Total</b>	<b>12,570.74</b>	<b>21,091.25</b>

**Note - I****Deferred Tax (Asset)**

Particulars	2022-23	2021-22
As Per Last Financial Statements	2,807.93	2,547.36
Incremental Deferred Tax Asset	(210.14)	260.57
<b>Total</b>	<b>2,497.79</b>	<b>2,807.93</b>

**Note - J****Other Non Current Assets**

Particulars	2022-23	2021-22
Security Deposits	12,660.67	7,870.12
<b>Total</b>	<b>12,660.67</b>	<b>7,870.12</b>

**Note - J****Inventories**

Particulars	2022-23	2021-22
Raw Material	1,00,771.05	73,600.29
Work-in-Progress	10,744.80	2,315.61
Finished Goods	49,698.15	46,234.73
Packing Material	2,28,978.10	1,10,614.07
<b>Total</b>	<b>3,90,191.90</b>	<b>2,32,764.70</b>



For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

  
Director.

**Note - K**

**Trade Receivables**

Particulars	2022-23	2021-22
Outstanding for more than six months	27,341.60	2,899.75
Others	379,970.50	541,791.51
<b>Total</b>	<b>407,312.10</b>	<b>544,691.26</b>

**Trade Receivables ageing schedule as at 31st March, 2023**

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	379,970.50	11,625.08	13,316.77	58.41	2,341.34	407,312.10
(ii) Undisputed	-	-	-	-	-	-
(iii) Disputed	-	-	-	-	-	-
(iv) Disputed	-	-	-	-	-	-

**Trade Receivables ageing schedule as at 31st March, 2022**

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	541,791.51	-	58.41	1,340.12	1,501.22	544,691.26
(ii) Undisputed	-	-	-	-	-	-
(iii) Disputed	-	-	-	-	-	-
(iv) Disputed	-	-	-	-	-	-

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*  
Director



**Note - L****Cash and Cash Equivalents**

Particulars	2022-23	2021-22
Cash-in-Hand	383.59	694.11
<b>Balance in Bank Accounts:</b>		
In Current Accounts	230.20	100,498.14
Deposit with bank held as Security against borrowing*	19,245.62	51,627.30
<b>Total</b>	<b>19,859.41</b>	<b>152,819.55</b>

\*Lien marked fixed deposit receipts is provided to bank/financial institution as security against borrowings which is not available for use.

**Note - M****Short-term Loans & Advances**

Particulars	2022-23	2021-22
Advance to Suppliers	24,063.62	31,114.65
<b>Total</b>	<b>24,063.62</b>	<b>31,114.65</b>

**Note - N****Other Current Assets**

Particulars	2022-23	2021-22
Balance with Revenue Authorities (Advance Tax)	16,000.00	20,000.00
Balance with Revenue Authorities (TDS)	480.18	739.42
IT Refund Receivables	-	258.85
Goods and Service Tax (Net)	49,720.17	42,529.96
<b>Total</b>	<b>66,200.35</b>	<b>63,528.23</b>

**Note - O****Revenue From Operations**

Particulars	2022-23	2021-22
Sale of Manufacturing Products (Net of Taxes)	1,559,857.79	1,904,794.98
Sale of Trading Goods (Net of Taxes)	62,960.05	217,725.07
<b>Total</b>	<b>1,622,817.84</b>	<b>217,725.07</b>

**Note - P****Other Income**

Particulars	2022-23	2021-22
Interest Income	2,080.28	1,884.25
Discount, Rebate & Rate Difference	63.39	5,736.40
Receipt from Insurance	2,785.33	-
Exchange Rate Difference	-	13,563
<b>Total</b>	<b>4,929.00</b>	<b>21,183.38</b>

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*

Director.





**Note - Q****Cost of Material Consumed**

Particulars	2022-23	2021-22
<b>Raw Material</b>		
Opening Stock	73,600.29	164,665.12
Add: Purchase during the year	439,470.17	341,372.02
	513,070.46	706,037.14
Less: Closing Stock	100,771.05	73,600.29
Raw Material Consumed (a)	412,299.41	411,070.53
<b>Packing Material</b>		
Opening Stock	110,614.07	111,720.54
Add: Purchase during the year	864,772.01	854,896.40
	975,386.08	966,616.94
Less: Closing Stock	228,978.10	110,614.07
Packing Material Consumed (b)	746,407.98	856,002.87
<b>Total (a+b)</b>	<b>1,158,707.39</b>	<b>1,267,073.40</b>

**Note - R****Change in Inventories of Finished Goods**

Particulars	2022-23	2021-22
<b>Work-in-progress</b>		
Opening Work-in-progress	2,315.61	4,612.40
Less: Closing Work-in-progress	10,744.60	2,315.61
(a)	(8,428.99)	2,296.79
<b>Finished Goods</b>		
Opening Finished Goods	46,234.73	15,055.13
Less: Closing Finished Goods	49,698.15	46,234.73
(b)	(3,463.42)	(31,179.60)
<b>Total (a+b)</b>	<b>(11,892.41)</b>	<b>(28,882.81)</b>

**Note - S****Employee Benefits Expense**

Particulars	2022-23	2021-22
Salaries & Wages	173,402.71	157,439.71
Bonus	5,185.00	12,630.03
Contribution to provident fund and other funds	2,480.19	2,585.45
Labour Welfare	163.00	-
<b>Total</b>	<b>181,230.90</b>	<b>172,655.19</b>

For Bio-Medica Laboratories Pvt. Ltd.,

  
 Director.

For Bio-Medica Laboratories Pvt. Ltd.,

  
 Director.


**Note - T****Finance Cost**

Particulars	2022-23	2021-22
Loan Processing Charges	4,375.00	9,373.46
Interest on Bank Loans	62,493.76	43,219.76
Interest on Others Loans	10,459.69	24,163.06
<b>Total</b>	<b>77,328.46</b>	<b>76,756.28</b>

**Note - U****Other Expenses**

Particulars	2022-23	2021-22
Audit Fees	300.00	300.00
Bank Charges	98.56	507.99
Commission	3,851.91	10,000.00
Design Charges	707.63	775.00
Electricity Expenses	36,235.63	23,187.72
Excise and Entry Tax	-	1,338.79
Freight & Documentation Expenses	21,603.91	27,815.72
Exchange Rate Diff	32.11	-
Late Fees, Interest & Penalties	11.43	244.83
Insurance Expenses	2,562.75	4,372.56
Lease Rent & Factory License	1,363.63	1,079.78
Legal & Professional Expense	2,852.50	5,952.15
License Fees	1,909.81	-
Miscellaneous Expenses	4,463.20	4,500.29
Manufacturing & Testing Expenses	2,125.45	776.44
Office & Factory Expenses	1,900.34	1,119.44
Power & Fuel	25,899.62	17,840.92
Printing & Stationary	753.96	492.82
Property tax	2,997.42	562.65
Repair & Maintenance	10,234.76	6,844.88
Supervision Charges	1,200.00	1,200.00
Telephone Expenses	231.91	97.42
Travelling Expenses	1,690.68	1,253.34
Vehicle Expenses	910.82	321.60
<b>Total</b>	<b>123,938.02</b>	<b>119,271.76</b>

**Note - U(1)****Payment to Auditors**

Particulars	2022-23	2021-22
As an Statutory Audit Fees	250.00	250.00
As Income Tax Consultancy	50.00	50.00
<b>Total</b>	<b>300.00</b>	<b>300.00</b>

For Bio-Medica Laboratories Pvt. Ltd.,

  
 Director.

For Bio-Medica Laboratories Pvt. Ltd.,



Director.



Note : II  
Property, Plants & Equipment and Intangible Assets

BIO MEDICA LABORATORIES PRIVATE, LIMITED

(Rs. in Hundred)

Assets	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	As on 01.04.22	Addition during the year	Sale during the year	As on 31.03.23	Up to 01.04.22	Provided during the year	Written back	Up to 31.03.23	As on 31.03.23	As on 31.03.22
<b>TANGIBLE ASSETS, Overhead Charges Provided</b>										
Leasehold Land & Building - Unit I	58,293.30	-	-	58,293.30	32,790.05	3,290.37	-	36,099.62	32,212.98	25,502.75
Leasehold Land & Building - Unit II	393,924.48	25,595.34	-	419,519.82	-	4,992.17	-	4,992.17	414,527.65	393,924.48
Computers & Data Processing Unit I	7,077.93	2,352.57	-	9,430.50	6,637.72	1,390.89	-	8,028.61	1,411.99	440.21
Computers & Data Processing Unit - II	-	474.55	-	474.55	-	145.18	-	145.18	329.40	-
Plant & Machinery Unit I	212,834.37	1,822.28	-	214,706.65	75,878.05	20,276.03	-	96,152.08	118,604.56	136,908.32
Plant & Machinery - Unit II	109,524.07	126,184.81	-	235,808.88	-	10,195.34	-	10,195.34	225,613.54	109,524.07
Lab Equipments Unit I	3,356.08	158.75	-	1,524.83	1,399.82	402.40	-	1,802.22	1,722.61	1,966.26
Lab Equipments - Unit II	15,921.30	5,402.98	-	21,424.28	-	2,699.38	-	2,699.38	18,724.90	15,521.30
Electric Installations - Unit I	13,093.43	1,441.01	-	14,535.24	-	1,834.95	-	1,834.95	12,700.29	13,093.43
Furniture & Fixtures Unit I	8,735.26	568.50	-	9,303.76	5,121.28	1,046.32	-	6,167.60	3,136.16	3,613.88
Furniture & Fixtures Unit I	-	8,757.50	-	8,757.50	-	816.16	-	816.16	5,941.34	-
Motor Vehicles	30,112.15	-	-	30,112.15	21,301.47	2,687.56	-	23,889.03	6,223.12	8,810.65
<b>Total</b>	<b>852,982.36</b>	<b>170,959.22</b>	<b>-</b>	<b>1,023,941.58</b>	<b>143,126.69</b>	<b>49,657.74</b>	<b>-</b>	<b>192,784.43</b>	<b>831,148.94</b>	<b>709,856.47</b>
<b>Previous Year</b>	<b>817,786.28</b>	<b>235,275.09</b>	<b>-</b>	<b>852,982.36</b>	<b>116,312.05</b>	<b>32,814.63</b>	<b>-</b>	<b>143,126.89</b>	<b>708,855.47</b>	<b>507,454.23</b>

Notes: (i) Long-term assets are provided on the various units basis (ii) Short-term assets are provided on the various units basis (iii) The Company has provided its property, plant and equipment as security against the loan taken from banks and financial institutions. (iv) The Company does not own any immovable property. The Company does not have any CWP and Intangible asset under development. The Company has not received its Property, Plant and Equipment during the year. (v) The Company does not own any immovable property. The Company does not have any CWP and Intangible asset under development. The Company has not received its Property, Plant and Equipment during the year. (vi) In respect of immovable properties of land and building that have been taken on lease and disclosed as fixed assets in the Financial statements, the lease agreements are in the name of the Company.

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.,

*[Signature]*  
Director.

